Skip to content
TrialScanner

NCT05001347

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2CompletedNBPLead

Registry record

Lead sponsor
I-Mab Biopharma US Limited
Conditions
Ovarian Cancer; Head and Neck Cancer; Non Small Cell Lung Cancer; Gastrointestinal Cancer; Triple Negative Breast Cancer
Primary completion
Feb 8, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05001347 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05001347: A Clinical Study of TJ004309... | TrialScanner